# Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

> **NCT01734785** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 607 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Empagliflozin + Linagliptin
- **DRUG:** Empagliflozin + Linagliptin
- **DRUG:** Empagliflozin + Linagliptin
- **DRUG:** Empagliflozin placebo + Linagliptin placebo
- **DRUG:** Empagliflozin + Linagliptin

## Key facts

- **NCT ID:** NCT01734785
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-08
- **Primary completion:** 2015-03-23
- **Final completion:** 2015-03-23
- **Target enrollment:** 607 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01734785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01734785, "Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01734785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*